New research is raising questions about whether popular weight-loss drugs could also affect cancer progression

Drugs like Ozempic, Wegovy, Mounjaro, and Zepbound changed the national conversation around weight loss and diabetes. Now, they are beginning to change the conversation around cancer.

At the 2026 American Society of Clinical Oncology Annual Meeting, researchers are expected to present new findings showing that GLP-1 drugs may help lower the risk of some cancers spreading to advanced stages. The research is still early, and experts stress that the drugs are not cancer cures. Still, the findings are drawing major attention because they point to a possible new link between obesity treatment and cancer outcomes.

The studies focus on obesity-related cancers, including breast, colorectal, liver, and lung cancers. Researchers say patients taking GLP-1 drugs appeared less likely to develop metastatic disease than patients taking certain other diabetes medications. Metastatic cancer happens when cancer spreads from one part of the body to another. It is often harder to treat and causes most cancer deaths.

One study presented ahead of ASCO 2026 reviewed health records from more than 12,000 patients. According to ASCO, patients taking GLP-1 drugs showed a 38% to 50% lower risk of progressing to stage IV cancer in several tumor types when compared with patients taking DPP-4 inhibitors, another class of diabetes drugs.

Stay Informed. Stay Empowered.

Sign up for FYH.News’ free weekly health update.

The findings are important because obesity and diabetes already play a major role in cancer risk across the United States. The National Cancer Institute reports that obesity is linked to at least 13 different cancers, including colorectal, liver, pancreatic, breast, and endometrial cancers. Rates of obesity and diabetes also remain disproportionately high in Black, Latino, Native, and low-income communities.

Researchers believe GLP-1 drugs may help because they improve several conditions tied to cancer growth. The drugs reduce inflammation, improve blood sugar control, and lower insulin resistance. Chronic inflammation and high insulin levels can create conditions that help tumors grow faster. Scientists are also studying whether GLP-1 pathways may directly affect cancer cells, although that research remains in the early stages.

“Our study found that use of GLP-1 drugs was associated with a meaningful reduction in cancer progression across four solid tumor types,” Dr. Mark David Orland of the Cleveland Clinic said during an ASCO press briefing.

Cancer researchers caution that the findings do not prove the drugs directly stop cancer spread. Most current studies rely on observational data, which means researchers look for patterns in large groups of patients. That type of research can show strong connections, but it cannot fully explain why those outcomes happened.

Doctors say other factors may have affected the results, including differences in weight loss, healthcare access, insurance coverage, nutrition, and overall health. Larger clinical trials are still needed before GLP-1 drugs can be considered part of standard cancer treatment.

Even with those limits, many oncologists believe the research deserves close attention because it reflects a larger shift happening in cancer care. Researchers increasingly view cancer as a disease connected to metabolism, inflammation, and overall body health, not only genetics. That idea is helping shape a growing area of research known as metabolic oncology.

The rising interest around GLP-1 drugs is also raising major health equity concerns. These medications remain expensive, and many insurance plans still limit coverage. Drug shortages have also made access difficult in some communities. Health advocates worry that if GLP-1 drugs eventually become part of cancer prevention or cancer care, underserved patients could once again face barriers to lifesaving treatment.

That concern is especially important for communities of color, which already experience higher rates of obesity, diabetes, delayed cancer diagnosis, and cancer deaths. Public health experts say new medical advances often reach these communities later because of cost, access issues, and lower participation in clinical trials.

Dr. Sherry Shen, a medical oncologist at Memorial Sloan Kettering Cancer Center, recently told The Washington Post that researchers still need more data about the long-term effects of GLP-1 drugs. “We don’t know all the good effects, but we don’t know all the bad effects either,” Shen said.

ASCO 2026 is expected to include several presentations examining how GLP-1 drugs may affect cancer survival, tumor growth, and patient outcomes. While researchers continue to study the science, the growing interest reflects how quickly these medications are moving beyond weight loss and diabetes treatment.

For patients and families affected by cancer, the research offers cautious hope but also many unanswered questions. If future studies confirm that GLP-1 drugs can help slow cancer progression, doctors and policymakers may face a larger challenge: making sure the communities most affected by obesity, diabetes, and cancer are not the last to benefit from one of the most important medical developments of the decade.

Stay Informed. Stay Empowered.

Sign up for FYH.News’ free weekly health update.